Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2007
Business Overview: The Company manufactures and sells apparatus, instruments, devices, and consumables for life science research. Operations are divided into the Apparatus and Instrumentation Business segment (continuing operations) and the Capital Equipment Business segment (discontinued operations, held for sale).
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2007 | Q1 2006 |
|---|---|---|
| Revenues (Continuing Ops) | $19,115 | $17,370 |
| Gross Profit | $9,421 | $8,880 |
| Gross Margin | 49.3% | 51.1% |
| Operating Income | $2,262 | $2,241 |
| Net Income (Total) | $496 | $540 |
| Diluted EPS (Total) | $0.02 | $0.02 |
| Cash from Operating Activities | $1,853 | $2,372 |
| Cash and Equivalents (Ending) | $9,571 | $11,902 |
| Long-Term Debt | $1,500 | $3,000 |
Material Changes vs. Prior Period
- Revenue Growth: Revenues from continuing operations increased 10.0% ($1.7 million) year-over-year. Excluding foreign exchange impacts, organic revenue growth was 5.0%. Growth was driven by Harvard Apparatus physiology/cell biology equipment and the recently acquired Anthos product lines.
- Margin Compression: Gross margin decreased from 51.1% to 49.3%. This was attributed to a higher sales mix of lower-margin Anthos products and under-absorption of manufacturing overhead due to vendor delays in spectrophotometer parts.
- Discontinued Operations: The Capital Equipment Business segment reported a net loss of $1.2 million for Q1 2007, compared to $1.1 million in Q1 2006. This segment remains classified as "held for sale."
- Debt Reduction: The Company repaid $1.5 million on its revolving credit facility, reducing outstanding debt from $3.0 million to $1.5 million.
- Cash Flow: Net cash provided by operating activities decreased to $1.9 million from $2.4 million, primarily due to the timing of payments for accounts payable and taxes.
Outlook, Risks, and Management Commentary
- Divestiture Strategy: Management anticipates selling the Capital Equipment Business segment in the first half of 2007. Proceeds are intended for debt repayment or "tuck-under" acquisitions.
- Financing Constraints: The sale of the Capital Equipment segment requires lender consent. Failure to obtain consent could trigger a default under the credit facility, potentially accelerating all indebtedness.
- Capital Expenditures: The Company expects to spend approximately $2.0 million on capital expenditures over the next 12 months.
- Foreign Exchange: A weaker U.S. dollar against the British Pound and Euro contributed to reported revenue growth. The Company does not currently hedge foreign currency positions.
- Operational Risks: Risks include the inability to complete the divestiture on attractive terms, delays in new product parts (specifically spectrophotometers), and potential impairment of goodwill or intangible assets.
Investor Verification Checklist
- Divestiture Timeline: Verify the status of the Capital Equipment Business sale and whether lender consent has been secured to avoid credit facility default.
- Supply Chain Issues: Monitor resolution of vendor delays affecting spectrophotometer production and the impact on gross margins.
- Debt Covenants: Confirm continued compliance with financial covenants (income, debt coverage, working capital) under the amended credit facility.
- Discontinued Operations: Track the net loss trajectory of the held-for-sale segment to ensure it does not erode cash reserves prior to sale.
- Acquisition Strategy: Assess the Company's ability to fund future "tuck-under" acquisitions given current cash balances and debt capacity.